ARO-ATXN2 Injection + Placebo
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Spinocerebellar Ataxia Type 2
Conditions
Spinocerebellar Ataxia Type 2
Trial Timeline
Dec 17, 2024 → Dec 1, 2026
NCT ID
NCT06672445About ARO-ATXN2 Injection + Placebo
ARO-ATXN2 Injection + Placebo is a phase 1 stage product being developed by Arrowhead Pharmaceuticals for Spinocerebellar Ataxia Type 2. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06672445. Target conditions include Spinocerebellar Ataxia Type 2.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06672445 | Phase 1 | Recruiting |
Competing Products
15 competing products in Spinocerebellar Ataxia Type 2
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2 | 51 |
| BIIB132 + BIIB132-Matching Placebo | Biogen | Phase 1 | 30 |
| IVIG | Baxter | Phase 2 | 49 |
| Intravenous Immune Globulin (IVIG) | Baxter | Phase 1 | 30 |
| Troriluzole + Placebo + Troriluzole | Biohaven | Phase 2/3 | 60 |
| BHV-4157 | Biohaven | Pre-clinical | 18 |
| troriluzole + Placebo | Biohaven | Phase 3 | 72 |